Advertisement

Loading...

Paradigm Biopharmaceuticals Limited

PBIGF•PNK
Healthcare
Biotechnology
$0.20
$0.02(11.33%)
U.S. Market opens in 14h 8m

Paradigm Biopharmaceuticals Limited (PBIGF) Stock Overview

Explore Paradigm Biopharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap89.2M
P/E Ratio-2.98
EPS (TTM)$-0.07
ROE-2.66%
Fundamental Analysis

AI Price Forecasts

1 Month$-0.20
3 Months$0.18
1 Year Target$0.22

PBIGF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Paradigm Biopharmaceuticals Limited (PBIGF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 52.94, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.22.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.98 and a market capitalization of 89.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
11.33%
5-Day Change
11.33%
1-Month Change
5.47%
3-Month Change
-14.03%
6-Month Change
8.32%
Year-to-Date (YTD) Change
-14.03%
1-Year Change
-47.36%
3-Year Change
-78.91%
5-Year Change
-88.87%
All-Time (Max) Change
-80.91%

Contact Information

https://www.paradigmbiopharma.com
61 3 9629 5566
500 Collins Street, Melbourne, VIC, 3000

Company Facts

IPO DateMay 10, 2019
CountryAU
Actively Trading

Frequently Asked Questions